SCHEMBL27019698

SCHEMBL27019698

Nc1ccc(C(=O)c2c[nH]c3nccc(Cl)c23)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.54
CDK9 P50750 2/20 0.54
CDK5 Q00535 2/20 0.54
LRRK2 Q5S007 2/20 0.54
CDC7 O00311 1/20 0.54
PLK4 O00444 1/20 0.54
CHEK1 O14757 1/20 0.54
MAPK13 O15264 1/20 0.54
PDPK1 O15530 1/20 0.54
DAPK3 O43293 1/20 0.54
DYRK3 O43781 1/20 0.54
ROCK2 O75116 1/20 0.54
PRKD3 O94806 1/20 0.54
MAP4K4 O95819 1/20 0.54
ABL1 P00519 1/20 0.54
PRKCG P05129 1/20 0.54
CDK1 P06493 1/20 0.54
ROS1 P08922 1/20 0.54
PIM1 P11309 1/20 0.54
PHKG2 P15735 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26977744 0.81 BTK (0.56) BTK
SCHEMBL30668776 0.80 CDK8 (0.62) CDK2CDK9CDK5LRRK2CDC7
SCHEMBL24672390 0.80 CDK8 (0.62) CDK2CDK9CDK5LRRK2CDC7
SCHEMBL17818839 0.78 CSNK2A1 (0.52) CDK2CDK9CDK5LRRK2CDC7
SCHEMBL30122008 0.78 CSNK2A1 (0.52) CDK2CDK9CDK5LRRK2CDC7
SCHEMBL857826 0.78 CYP3A4 (0.47) CDK2CDK9CDK5LRRK2CDC7
SCHEMBL1839435 0.77 LRRK2 (0.51) CDK2CDK9CDK5LRRK2CDC7
SCHEMBL856983 0.76 CYP3A4 (0.47) CDK2CDK9CDK5LRRK2CDC7
SCHEMBL297561 0.75 CYP3A4 (0.61) CDK2CDK9CDK5LRRK2CDC7
SCHEMBL857838 0.75 BTK (0.52) BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018150-A1 SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF ARROMAX PHARMATECH CO., LTD. (CN) 2024-01-18 US disclosed
US-20240018150-A1 SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF ARROMAX PHARMATECH CO., LTD. (CN) 2024-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018150-A1 SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF BTK, SYK, LCK CDK2 377/4885CDK9 164/4885CDK5 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.